Advances in Ancillary Therapies to Enhance Post-Transplant Survivorship
To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.
Starts On:
7/1/2019: 12:00 AM
Ends On:
6/30/2020: 12:00 AM
Session Type:
Internet Activity Enduring Material
Credits:
0.5
Description:
Assistant Professor, Medicine
Division of Oncology
Section of Bone Marrow Transplant
Disclosures
Financial Relationships: Nothing to disclose
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology & Hematology, September 21-22, 2018, which was supported in part by Celgene Corporation, Ipsen Biopharmaceuticals Inc., Takeda Oncology, Lilly USA LLC, Novartis Pharmaceuticals and Seattle Genetics Inc.
Financial Relationships:
• Speakers Bureau / Honoraria: Seattle Genetics
Ramaswamy Govindan, MD, Co-Chair
Financial Relationships:
• Consulting/ Advisory, Self Committees: Astrazenca LP, Iniivata Ltd, Merck & Co., Pfizer Pharmaceuticals, Roche and AbbVie Inc.
Krystal F. Prater, RN, BSN
Financial Relationships: Nothing to disclose
Rachel Sanger, DNP, APRN, ANCC-BC
Financial Relationships: Nothing to disclose
Saiama N. Waqar, MBBS, MSCI, Co-Chair
Financial Relationships: Nothing to disclose
Peter Westervelt, MD, PhD, Co-Chair
Financial Relationships:
• Research Support/Grants: Astellas Pharma Inc. and Novartis Corporation
Faculty
Iskra Pusic, MDAssistant Professor, Medicine
Division of Oncology
Section of Bone Marrow Transplant
Disclosures
Financial Relationships: Nothing to disclose
Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Advances in Oncology & Hematology, September 21-22, 2018, which was supported in part by Celgene Corporation, Ipsen Biopharmaceuticals Inc., Takeda Oncology, Lilly USA LLC, Novartis Pharmaceuticals and Seattle Genetics Inc.
Planning Committee
Holly S. Comer, NP, ANP-BCFinancial Relationships:
• Speakers Bureau / Honoraria: Seattle Genetics
Ramaswamy Govindan, MD, Co-Chair
Financial Relationships:
• Consulting/ Advisory, Self Committees: Astrazenca LP, Iniivata Ltd, Merck & Co., Pfizer Pharmaceuticals, Roche and AbbVie Inc.
Krystal F. Prater, RN, BSN
Financial Relationships: Nothing to disclose
Rachel Sanger, DNP, APRN, ANCC-BC
Financial Relationships: Nothing to disclose
Saiama N. Waqar, MBBS, MSCI, Co-Chair
Financial Relationships: Nothing to disclose
Peter Westervelt, MD, PhD, Co-Chair
Financial Relationships:
• Research Support/Grants: Astellas Pharma Inc. and Novartis Corporation
Objectives:
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- State advances in ancillary therapies to enhance post-transplant survivorship.
Additional Information:
Target Audience: This course is designed by and for medical oncologists, radiation oncologists, hematologists, pathologists, radiation oncologists, primary care physicians and those that perform blood and marrow transplantation, as well as physician assistants, nurses and nurse practitioners.
Publication Date: July 1, 2019
Expiration Date: June 30, 2020
Target Audience: This course is designed by and for medical oncologists, radiation oncologists, hematologists, pathologists, radiation oncologists, primary care physicians and those that perform blood and marrow transplantation, as well as physician assistants, nurses and nurse practitioners.
Publication Date: July 1, 2019
Expiration Date: June 30, 2020
Accreditation Information:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Awarded for this Activity:
Credit Statement:
American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
References:
- Majhail et al.Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501
- John R. Wingard et al. JCO 2011;29:2230-2239
- Inamoto and Lee; Haematologica 2017;102:614-625
- Carpenter; Blood 2016;127:2824-2832
Disclosure Information:
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.
These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
